701 related articles for article (PubMed ID: 14993230)
21. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
Buzaid AC; Mathias Cde C; Perazzo F; Simon SD; Fein L; Hidalgo J; Murad AM; Esser R; Senger S; Lerzo G
Clin Colorectal Cancer; 2010 Dec; 9(5):282-9. PubMed ID: 21208842
[TBL] [Abstract][Full Text] [Related]
22. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ
Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Souglakos J; Kalykaki A; Vamvakas L; Androulakis N; Kalbakis K; Agelaki S; Vardakis N; Tzardi M; Kotsakis AP; Gioulbasanis J; Tsetis D; Sfakiotaki G; Chatzidaki D; Mavroudis D; Georgoulias V
Ann Oncol; 2007 Feb; 18(2):305-10. PubMed ID: 17079693
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab for the treatment of colorectal cancer.
Jonker DJ; O'Callaghan CJ; Karapetis CS; Zalcberg JR; Tu D; Au HJ; Berry SR; Krahn M; Price T; Simes RJ; Tebbutt NC; van Hazel G; Wierzbicki R; Langer C; Moore MJ
N Engl J Med; 2007 Nov; 357(20):2040-8. PubMed ID: 18003960
[TBL] [Abstract][Full Text] [Related]
25. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer.
Steele N; Anthony A; Saunders M; Esmarck B; Ehrnrooth E; Kristjansen PE; Nihlén A; Hansen LT; Cassidy J
Br J Cancer; 2012 Feb; 106(5):793-8. PubMed ID: 22315057
[TBL] [Abstract][Full Text] [Related]
26. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
Cleary JM; McRee AJ; Shapiro GI; Tolaney SM; O'Neil BH; Kearns JD; Mathews S; Nering R; MacBeath G; Czibere A; Sharma S; Korn WM
Invest New Drugs; 2017 Feb; 35(1):68-78. PubMed ID: 27853996
[TBL] [Abstract][Full Text] [Related]
27. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
28. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
[TBL] [Abstract][Full Text] [Related]
29. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
Su X; Lacouture ME; Jia Y; Wu S
Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
[TBL] [Abstract][Full Text] [Related]
30. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
31. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
33. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
[TBL] [Abstract][Full Text] [Related]
34. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.
Neyns B; Sadones J; Joosens E; Bouttens F; Verbeke L; Baurain JF; D'Hondt L; Strauven T; Chaskis C; In't Veld P; Michotte A; De Greve J
Ann Oncol; 2009 Sep; 20(9):1596-1603. PubMed ID: 19491283
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
36. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab: in the treatment of metastatic colorectal cancer.
Reynolds NA; Wagstaff AJ
Drugs; 2004; 64(1):109-18; discussion 119-121. PubMed ID: 14723561
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Meyerhardt JA; Ancukiewicz M; Abrams TA; Schrag D; Enzinger PC; Chan JA; Kulke MH; Wolpin BM; Goldstein M; Blaszkowsky L; Zhu AX; Elliott M; Regan E; Jain RK; Duda DG
PLoS One; 2012; 7(6):e38231. PubMed ID: 22701615
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
